AI Article Synopsis

Article Abstract

Akinesia, hypokinesia, and bradykinesia are extensively used to describe motor execution disturbances, but are applied inconsistently and cover more conditions than their Greek translations would suggest. We investigated the origins and changes in meaning of these terms over time, particularly in relation to Parkinson's disease (PD). We searched the literature from 1817 to 2015 for use and interpretation of the words akinesia, bradykinesia, hypokinesia, and PD. We found that akinesia and hypokinesia appeared as terms in the 19th century, opposite to hyperkinesia, but were used in the context of PD since 1920, while at the same time the 'bradykinetic syndrome' was introduced. Use of all terms increased in this period due to the encephalitis-lethargica-epidemic, and increased again with the discovery of levodopa from 1961. With the extensive use of criteria sets from the 1980s, bradykinesia replaced akinesia as the most commonly used term. The advent of the internet led to an increase in publications and an associated increase in heterogeneity in the use of the terms. This review shows the variation over time and the lack of unity in the terminology used to describe the range of movement execution disturbances. The current terminology fails to capture the nuances of the challenges we face in documenting these disturbances. We therefore recommend that the current situation may benefit from an objective and computationally solid approach using insights from network and circuitry technology and new developments in assessment technology. It is expected that this will contribute to a new framework for terminology in movement disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2017.01.010DOI Listing

Publication Analysis

Top Keywords

akinesia bradykinesia
8
bradykinesia hypokinesia
8
akinesia hypokinesia
8
execution disturbances
8
terminology
4
terminology akinesia
4
bradykinesia
4
hypokinesia
4
hypokinesia future
4
akinesia
4

Similar Publications

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the degeneration of dopamine neurons in the substantia nigra pars compacta, leading to motor and non-motor symptoms. While motor symptoms such as rigidity, tremor, bradykinesia/akinesia, and postural instability are well-recognized, non-motor symptoms including cognitive decline, depression, and anxiety also significantly impact patients' quality of life. Preclinical research utilizing animal models has been instrumental in understanding PD pathophysiology and exploring therapeutic interventions.

View Article and Find Full Text PDF

Pathophysiology of Motor Control Abnormalities in Parkinson's Disease.

Cold Spring Harb Perspect Med

December 2024

Emory National Primate Research Center and School of Medicine, Emory University, Atlanta, Georgia 30329, USA

Research in the last few decades has brought us closer to an understanding of the brain circuit abnormalities that underlie parkinsonian motor signs. This article summarizes the current knowledge in this rapidly emerging field. Traditional observations of activity changes of basal ganglia neurons that accompany akinesia and bradykinesia have been supplemented with new knowledge regarding specific pathophysiologic changes that are associated with other parkinsonian signs, such as tremor and gait impairments.

View Article and Find Full Text PDF

The progressive decline of dopaminergic neurons in Parkinson's disease (PD) has been linked to an imbalance in energy and the failure of mitochondrial function. AMP-activated protein kinase (AMPK), the major intracellular energy sensor, regulates energy balance, and damage to nigral dopaminergic neurons induced by 6-hydroxydopamine (6-OHDA) is exacerbated in the absence of AMPK activity. This study aimed to examine the potential therapeutic advantages of AdipoRon, an AMPK activator, on motor function and mitochondrial homeostasis in a 6-OHDA-induced PD model.

View Article and Find Full Text PDF

Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease.

Chem Biol Drug Des

September 2024

Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, India.

Parkinson's disease (PD) stands as the second most common neurological disorder after Alzheimer's disease, primarily affecting the elderly population and significantly compromising their quality of life. The precise etiology of PD remains elusive, but recent research has shed light on potential factors, including the formation of α-synuclein aggregates, oxidative stress, neurotransmitter imbalances, and dopaminergic neurodegeneration in the substantia nigra pars compacta (SNpc) region of the brain, culminating in motor symptoms such as bradykinesia, akinesia, tremors, and rigidity. Monoamine oxidase (MAO) is an essential enzyme, comprising two isoforms, MAO-A and MAO-B, responsible for the oxidation of monoamines such as dopamine.

View Article and Find Full Text PDF

Effect of patent complete revascularization on the akinetic myocardial segments.

Interdiscip Cardiovasc Thorac Surg

August 2024

Cardiovascular Center, Myongji Hospital, Gyeonggido, Republic of Korea.

Objectives: The aims of the study were (i) to examine the changes in echocardiographic parameters and (ii) to compare the fate of myocardial segments with akinesia and without akinesia on preoperative echocardiography after coronary artery bypass grafting.

Methods: One hundred one patients who underwent complete revascularization, who were assessed by preoperative, before discharge, postoperative 3- and 12-month echocardiographic examinations, and who showed all patent grafts at postoperative 1-year angiograms were included. Echocardiographic left ventricular ejection fraction was assessed, and a 16-segment model was adopted for regional analysis of the left ventricle.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!